The results revealed that the phosphorylation of S6, AKT and mTOR was significantly reduced in the sensitive cells compared to that in the resistant cells, which suggested that BYL719 can potentially be used in NPC treatment. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.